中 | EN

Investors

(1) POLL RESULTS OF THE 2024 ANNUAL GENERAL MEETING HELD ON MAY 20, 2025; (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION; AND (3) DISSOLUTION OF THE SUPERVISORY COMMITTEE AND RESIGNATION OF SUPERVISORS
2025-05-20
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR CLINICAL TRIALS IN BOTH CHINA AND U.S. FOR ITERATIVE MRNA HERPES ZOSTER VACCINE ITS HUMORAL AND CELLULAR IMMUNITY WAS SIGNIFICANTLY HIGHER THAN THOSE OF INTERNATIONAL BENCHMARK PRODUCTS
2025-05-19
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2025
2025-05-07
FORM OF PROXY OF HOLDERS OF H SHARES FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 20, 2025
2025-04-25
NOTICE OF 2024 ANNUAL GENERAL MEETING
2025-04-25
CIRCULAR OF 2024 ANNUAL GENERAL MEETING
2025-04-25
2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
2025-04-25
2024 ANNUAL REPORT
2025-04-25
PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
2025-04-25
VOLUNTARY ANNOUNCEMENT - PROPOSED ADOPTION OF SHARE INCENTIVE SCHEME
2025-04-17
VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF PRESIDENT OF THE GROUP
2025-04-17
CHANGE IN COMPOSITION OF BOARD COMMITTEES
2025-04-17
RESIGNATION OF DIRECTORS
2025-04-13
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2025
2025-04-10
VOLUNTARY ANNOUNCEMENT - SERUM-FREE ITERATIVE RABIES VACCINE ACCEPTED FOR MARKET REGISTRATION
2025-04-07
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024
2025-03-28
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2025
2025-03-27
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025
2025-03-27
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2024
2025-03-27
VOLUNTARY ANNOUNCEMENT APPROVAL BY THE U.S. FDA FOR CLINICAL TRIAL OF THE MRNA HERPES ZOSTER VACCINE ITS HUMORAL AND CELLULAR IMMUNITY WAS SIGNIFICANTLY HIGHER THAN THOSE OF INTERNATIONALLY COMMERCIALLY AVAILABLE RECOMBINANT SUBUNIT VACCINES
2025-03-23
NOTICE OF BOARD MEETING
2025-03-18
VOLUNTARY ANNOUNCEMENT - SIGNIFICANT DECREASE IN LOSS OF THE COMPANY'S RESULTS
2025-03-17
VOLUNTARY ANNOUNCEMENT - ITERATIVE SERUM-FREE RABIES VACCINE: PHASE III CLINICAL TRIALS COMPLETED, PRODUCTION LICENSE OBTAINED AND APPLICATION FOR DRUG MARKETING REGISTRATION TO BE SUBMITTED
2025-03-12
VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL OF THE ITERATIVE-PROCESS HIGHLY-EFFECTIVE HUMAN DIPLOID RABIES VACCINE APPROVED FURTHER CEMENTING OUR LEADING POSITION IN GLOBAL RABIES VACCINE INDUSTRY
2025-03-09
Next Day Disclosure Return
2025-03-06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2025
2025-03-06
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025
2025-03-06
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2024
2025-03-06
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024
2025-03-06
PLACING OF NEW H SHARES UNDER GENERAL MANDATE
2025-02-28
VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL OF MRNA RESPIRATORY SYNCYTIAL VIRUS VACCINES APPROVED BY FDA WITH THEIR HUMORAL AND CELLULAR IMMUNITY SIGNIFICANTLY HIGHER THAN THOSE OF INTERNATIONALLY MARKETED PRODUCTS
2025-02-26
VOLUNTARY ANNOUNCEMENT - IMMUNE INDICATORS OF THE MRNA SHINGLES/HERPES ZOSTER VACCINES WERE SIGNIFICANTLY HIGHER THAN THOSE OF INTERNATIONAL COMMERCIALLY AVAILABLE RECOMBINANT SUBUNIT VACCINES APPLICATION FOR CLINICAL TRIAL OF THE PRODUCT IN THE U.S.
2025-02-23
VOLUNTARY ANNOUNCEMENT - FULL INTEGRATION OF DEEPSEEK TO ACHIEVE STRATEGIC UPGRADE OF "AI + INTELLIGENT VACCINE ENTERPRISE"
2025-02-23
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF THE MRNA SHINGLES/HERPES ZOSTER VACCINES T-CELL IMMUNITY, IgG ANTIBODY TITERS AND FLUORESCENT ANTIBODY TO MEMBRANE ANTIGEN TITERS WERE SIGNIFICANTLY HIGHER THAN THOSE OF COMMERCIALLY AVAILABLE RECOMBINANT SUBUNIT VACCINES
2025-02-11
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025
2025-02-05
VOLUNTARY ANNOUNCEMENT - HUMORAL AND CELLULAR IMMUNITY OF THE MRNA RSV VACCINE WERE SIGNIFICANTLY HIGHER THAN THOSE OF INTERNATIONALLY MARKETED PRODUCTS APPLICATION FOR CLINICAL TRIAL IN THE U.S.
2025-02-05
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2024
2025-01-06
VOLUNTARY ANNOUNCEMENT - SECOND GENERATION OF HIGHLY-EFFECTIVE ABSORBED TETANUS VACCINE OBTAINED THE CLINICAL TRIAL APPROVAL 
2024-12-19
VOLUNTARY ANNOUNCEMENT - SUSPENSION CULTURE INFLUENZA VACCINE (MDCK CELLS) WITH NEW TECHNOLOGICAL ROUTE OBTAINED THE CLINICAL TRIAL APPROVAL 
2024-12-19
CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG
2024-11-25
VOLUNTARY ANNOUNCEMENT - ANNOUNCEMENT ON THE 2024 CORPORATE DAY EVENT
2024-11-25
VOLUNTARY ANNOUNCEMENT - SUBMISSION OF THE PRE-APPLICATION FOR MARKETING REGISTRATION OF THE ITERATIVE SERUM-FREE RABIES VACCINE
2024-11-17
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF THE ITERATIVE-PROCESS HIGHLY-EFFECTIVE HUMAN DIPLOID RABIES VACCINE
2024-11-07
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024
2024-11-04
VOLUNTARY ANNOUNCEMENT - 13-VALENT PNEUMONIA CONJUGATE VACCINE PHASE III CLINICAL TRIALS COMPLETED, PRODUCTION LICENSE OBTAINED AND APPLICATION FOR DRUG MARKETING REGISTRATION DULY SUBMITTED
2024-10-31
VOLUNTARY ANNOUNCEMENT - MRNA RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE OBTAINED THE CLINICAL TRIAL APPROVAL
2024-10-30
VOLUNTARY ANNOUNCEMENT - UNBLINDING OF DATA FROM PHASE III CLINICAL TRIAL OF ITERATIVE SERUM-FREE RABIES VACCINE: PRE-DEFINED CLINICAL OBJECTIVES MET WITH GOOD IMMUNOGENICITY AND SAFETY
2024-10-06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024
2024-10-04
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
2024-09-03
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024
2024-08-29
RE-DESIGNATION OF DIRECTORS
2024-08-29
VOLUNTARY ANNOUNCEMENT - OFFICIAL APPLICATION FOR CLINICAL TRIALS FOR QUADRIVALENT INFLUENZA VIRUS VACCINE (MDCK CELLS) SUBMITTED
2024-08-29
VOLUNTARY ANNOUNCEMENT - OFFICIAL APPLICATION FOR CLINICAL TRIALS FOR ABSORBED TETANUS VACCINE SUBMITTED (43K
2024-08-29
VOLUNTARY ANNOUNCEMENT - PRE-APPLICATIONS FOR CLINICAL TRIALS FOR MRNA RSV AND MRNA SHINGLES/HERPES ZOSTER VACCINES OF AIM VACCINE SUBMITTED TO FDA
2024-08-29
NOTICE OF BOARD MEETING
2024-08-19
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
2024-08-02
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
2024-07-02
VOLUNTARY ANNOUNCEMENT - PRE-APPLICATIONS FOR CLINICAL TRIALS FOR TWO MRNA VACCINES OF RESPIRATORY SYNCYTIAL VIRUS (RSV) AND SHINGLES/HERPES ZOSTER OF AIM VACCINE SUBMITTED
2024-06-04
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
2024-06-04
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 20, 2024
2024-05-20
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
2024-05-07
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
2024-05-07
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
2024-05-07
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
2024-05-07
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
2024-05-07
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
2024-05-07
FORM OF PROXY OF HOLDERS OF H SHARES FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 20, 2024
2024-04-25
NOTICE OF 2023 ANNUAL GENERAL MEETING
2024-04-25
CIRCULAR OF 2023 ANNUAL GENERAL MEETING
2024-04-25
VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDING OF H SHARES BY THE CONTROLLING SHAREHOLDER
2024-04-18
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
2024-04-03
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
2024-04-03
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
2024-04-03
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
2024-04-03
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
2024-04-03
VOLUNTARY ANNOUNCEMENT - PRE-APPLICATION FOR CLINICAL TRIALS FOR HAEMOPHILUS INFLUENZAE TYPE B CONJUGATE VACCINE SUBMIT
2024-03-28
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
2024-03-28
VOLUNTARY ANNOUNCEMENT - PRE-APPLICATION FOR CLINICAL TRIALS FOR QUADRIVALENT INFLUENZA VIRUS VACCINE (MDCK CELLS) SUBMITTED
2024-03-28
VOLUNTARY ANNOUNCEMENT - PRE-APPLICATION FOR CLINICAL TRIALS FOR NOVEL-PROCESS HIGHLY-EFFECTIVE HUMAN DIPLOID RABIES VACCINE SUBMITTED
2024-03-26
NOTICE OF BOARD MEETING
2024-03-15
VOLUNTARY ANNOUNCEMENT - PRE-APPLICATION FOR CLINICAL TRIALS FOR ABSORBED TETANUS VACCINE SUBMITTED
2024-03-04
VOLUNTARY ANNOUNCEMENT - INITIATION OF PHASE II CLINICAL TRIAL OF TETRAVALENT MENINGOCOCCAL CONJUGATE VACCINE
2024-03-04
PROFIT WARNING
2024-03-04
VOLUNTARY ANNOUNCEMENT - COMPLETION OF THE LAYOUT OF ITERATIVE RABIES VACCINE PRODUCTS AND FULLY ADVANCING THE RESEARCH AND DEVELOPMENT OF THE PRODUCT SERIES
2024-03-04
VOLUNTARY ANNOUNCEMENT - COMPLETION OF THE LAYOUT OF ITERATIVE PNEUMONIA VACCINE PRODUCTS AND FULLY ADVANCING THE RESEARCH AND DEVELOPMENT OF THE PRODUCT SERIES
2024-03-04
VOLUNTARY ANNOUNCEMENT - EXPECTED COMPLETION OF APPLICATION FOR MARKETING OF 13-VALENT PNEUMONIA CONJUGATE VACCINE, ITERATIVE SERUM-FREE RABIES VACCINE AND 23-VALENT PNEUMONIA POLYSACCHARIDE VACCINE IN 2024
2024-03-04
VOLUNTARY ANNOUNCEMENT - PRE-APPLICATION FOR MARKETING REGISTRATION FOR 13-VALENT PNEUMONIA CONJUGATE VACCINE SUBMITTED
2024-03-01
Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
2024-03-01
(1) POLL RESULTS OF THE 2024 FIRST EXTRAORDINARY GENERAL MEETING HELD ON FEBRUARY 29, 2024; (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION; AND (3) APPOINTMENTS OF THE EXECUTIVE VICE-CHAIRMAN AND THE VICE-CHAIRMAN OF THE BOARD HAVING BECOME EFFECTIVE
2024-02-29
(1) Notification Letter to Non-registered Shareholder and (2) Updated Arrangement of Electronic Dissemination of Corporate Communications
2024-02-08
FORM OF PROXY OF HOLDERS OF H SHARES FOR USE AT THE 2024 FIRST EXTRAORDINARY GENERAL MEETING TO BE HELD ON FEBRUARY 29, 2024
2024-02-08
PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND NOTICE OF THE 2024 FIRST EXTRAORDINARY GENERAL MEETING
2024-02-08
NOTICE OF THE 2024 FIRST EXTRAORDINARY GENERAL MEETING
2024-02-08
(1) ELECTION OF THE EXECUTIVE VICE-CHAIRMAN AND THE VICE-CHAIRMAN OF THE BOARD; AND (2) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
2024-02-08
CLOSURE OF REGISTER OF MEMBERS
2024-02-07
Arrangement of Electronic Dissemination of Corporate Communications
2024-02-01
New Arrangements on Dissemination of Corporate Communications
2024-02-01
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
2024-02-01
VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDING OF H SHARES BY THE CONTROLLING SHAREHOLDER
2024-01-10
VOLUNTARY ANNOUNCEMENT - FURTHER CONTINUOUS INCREASE IN SHAREHOLDING OF H SHARES BY THE CONTROLLING SHAREHOLDER
2024-01-02
© 2022 艾美疫苗股份有限公司 All rights reserved. 京ICP备20027818号-1 京公网安备11010502045274号